All
Expanding Our Dermatologic Beauty Atlas
Zoe Diana Draelos, MD, reviews the importance of expanding societal and cosmetic ideas of beauty to be reflective of all skin types, ages, and more.
Cyltezo Added to Express Scripts' National Preferred Formulary
Coverage for eligible patients began July 12, 2023.
July is UV Awareness Month
Summer months bring time outside. With July being UV Awareness month, we are highlighting some past articles you may have missed.
Alopecia Areata Leads to Cost, Time Burdens in Cohort of Patients From Japan
Real-world data demonstrated marked impacts on the economy on a national and personal level.
Maximizing Care With Nurse Practitioners and Physician Assistants
Nurse practitioners and physician assistants play a crucial role in dermatology, and Dermatology Times is proud to curate content embracing and empowering the NP/PA community.
Study Investigates Secukinumab’s Effects on Cytokines in Patients With Psoriasis
IL-17A was antagonized by secukinumab, while several other serum levels were decreased in expression.
POLL: What Topic are you Most Looking Forward to at the Society for Pediatric Dermatology Meeting?
Answer today's poll below.
Sneak Peek of the 2023 Society for Pediatric Dermatology Meeting
Course directors share which pearls, sessions, and insights they are looking forward to this weekend in Asheville, North Carolina.
Plan Your Trip: What to do While Visiting Asheville
When sessions conclude, you will find no shortage of opportunities to keep you busy.
Comorbidity Burden Continues to Rise After Diagnosis of Hidradenitis Suppurativa
A study found that the costs associated with managing comorbidities of hidradenitis suppurativa increase among adults and adolescents.
Pointers With Portela: Best Time to Start Using Retinol
In this week’s Pointers With Portela, the 208SkinDoc answers frequently asked questions about retinol use.
OTC Treatment Options for Pesky Summer Rashes
The American Skin Association estimated that 50 million Americans are exposed to urushiol yearly, the most common contact allergen in the US.
Influencing and Improving Photoprotection Behaviors in Patients With Xeroderma Pigmentosum
Patients with the rare autosomal recessive genodermatosis are prone to extreme photosensitivity and changes in skin pigmentation.
Soligenix Expands Synthetic Hypericin Psoriasis Study
Additional patients will be enrolled in the phase 2a study after a clear biological signal was demonstrated in initial participants.
New Positive Topline Results From Ruxolitinib Phase 3 Trial for Pediatric AD
The TRuE-AD3 study met its primary endpoint of IGA-TS improvement from baseline at week 8.
DFD-29 Achieves Phase 3 Co-Primary and All Secondary Endpoints for Papulopustular Rosacea Treatment
Based on the positive topline phase 3 results, Journey Medical plans to submit a New Drug Application to the FDA in the second half of 2023.
AAD and VStrong Vitiligo Support Community Receive Inaugural Incyte Ingenuity Awards in Vitiligo
Incyte representative Todd Edwards discusses how the awards help address challenges faced by patients with vitiligo.
Topical Therapeutic Shows Significant Improvement in Mild-to-Moderate Atopic Dermatitis
Alphyn Biologics announced positive results from their Phase 2a trial of AB-101a will lead to a multinational Phase 2b trial soon.
Microneedling Produces Beneficial Acne Vulgaris Outcomes Without Disrupting Skin Structure or Microbiome
Researchers sought to challenge the perception of microneedling as disruptive to the skin and disease states.
Pediatric Necrobiosis Lipoidica Yields Treatment Failure Rate of 40%
Researchers conducted a review of treatments for the rare disease in the pediatric population.
POLL: What is the Average Diagnosis Delay for Patients With HS?
Click here to answer this week's HS poll.
POLL: Are You Attending the 2023 Society for Pediatric Dermatology Meeting?
The 2023 Society for Pediatric Dermatology Meeting kicks off in Asheville, North Carolina, on July 13.
Spesolimab Effective in Treating Generalized Pustular Psoriasis Flares
Boehringer Ingelheim announced that novel antibody treatment can interfere in the IL-36 signaling pathway, reducing flares.
Laura Bush, DMSc, PA-C, DFAAPA, Appointed Next President of SDPA
Bush revealed what she is looking forward to in the coming year and the goals she wants to accomplish.
AD Patient Self-Confidence and Satisfaction Improved With Dupilumab Self-Injection
Dupilumab self-injection has been available to patients in Japan since May 2019.
Blue Light Irradiation Induces Minimal Pigmentation Change in Patients With Melasma
Compared to patients without melasma, blue light irradiation caused minimal changes in patients with melasma.
POLL: Do You Treat More Male or Female Patients With Melanoma?
Click here to answer this week's poll.
Researchers Study Possible Link Between Atopic Dermatitis and Tooth Agenesis
Examining the genes and signaling pathways of development of atopic dermatitis and tooth agenesis reveals possible link between the two diseases.
Hidradenitis Suppurativa Treated with Sonelokimab Shows Significant Improvement
In a clinical trial, patients reported improved quality of life after 12 weeks on sonelokimab.
Dupilumab Effective in Reducing New Allergies and Slowing Atopic March
Findings indicate no rebound effect when participants discontinue dupilumab.
